The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CPRX Detailed Price Forecast - CNN Money||View CPRX Detailed Summary - Google Finance|
|View CPRX Detailed Summary - Yahoo! Finance||View CPRX Stock Research & Analysis - Zacks.com|
|View CPRX Trends & Analysis - Trade-Ideas||View CPRX Major Holders - Barrons|
|View CPRX Call Transcripts - NASDAQ||View CPRX Breaking News & Analysis - Seeking Alpha|
|View CPRX Annual Report - CompanySpotlight.com||View CPRX OTC Short Report - OTCShortReport.com|
|View CPRX Fundamentals - TradeKing||View CPRX SEC Filings - Bar Chart|
|View Historical Prices for CPRX - The WSJ||View Performance/Total Return for CPRX - Morningstar|
|View the Analyst Estimates for CPRX - MarketWatch||View the Earnings History for CPRX - CNBC|
|View the CPRX Earnings - StockMarketWatch||View CPRX Buy or Sell Recommendations - MacroAxis|
|View the CPRX Bullish Patterns - American Bulls||View CPRX Short Pain Metrics - ShortPainBot.com|
|View CPRX Stock Mentions - StockTwits||View CPRX Stock Mentions - PennyStockTweets|
|View CPRX Stock Mentions - Twitter||View CPRX Investment Forum News - Investor Hub|
|View CPRX Stock Mentions - Yahoo! Message Board||View CPRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for CPRX - SECform4.com||View Insider Transactions for CPRX - Insider Cow|
|View CPRX Major Holdings Summary - CNBC||View Insider Disclosure for CPRX - OTC Markets|
|View Insider Transactions for CPRX - Yahoo! Finance||View Institutional Holdings for CPRX - NASDAQ|
|View CPRX Stock Insight & Charts - FinViz.com||View CPRX Investment Charts - StockCharts.com|
|View CPRX Stock Overview & Charts - BarChart||View CPRX User Generated Charts - Trading View|
Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets
Posted on Tuesday December 18, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.
Does Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Have A Volatile Share Price?
Posted on Friday December 14, 2018
If you own shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Tuesday December 11, 2018
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases today announced that the company will host a conference call and webcast on December 13, 2018 at 8:30 AM ET to discuss its commercialization plan for Firdapse®, including the cost of therapy. “We look forward to providing the details of the commercial launch plan for Firdapse for the treatment of LEMS, as well as our plan for achieving our stated objective of affordable access to Firdapse for all,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. A webcast replay will be available on the Catalyst website following the call by visiting the Investor page of the company's website at www.catalystpharma.com.